Compare Stocks → Mysterious Gold Leverage Just Announced (From Stansberry Research) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:BCLINASDAQ:ERYPNASDAQ:FENCNASDAQ:IDRA Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBCLIBrainstorm Cell Therapeutics$0.53-1.8%$0.47$0.13▼$3.34$36.36M0.28978,228 shs273,815 shsERYPERYTECH Pharma$3.10$4.66$0.30▼$1.47$105.77M2.6993,510 shsN/AFENCFennec Pharmaceuticals$9.16+1.0%$10.05$6.30▼$11.92$248.24M0.38115,102 shs120,030 shsIDRAIdera Pharmaceuticals$0.50$0.22▼$8.67$450.52M1.25464,030 shs21,870 shs7 Stocks to Buy And Hold ForeverClick the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBCLIBrainstorm Cell Therapeutics+3.81%+0.78%-16.79%+75.69%-80.40%ERYPERYTECH Pharma0.00%0.00%0.00%-34.04%+254.29%FENCFennec Pharmaceuticals-1.84%-6.49%-17.55%-12.96%+14.09%IDRAIdera Pharmaceuticals0.00%0.00%0.00%0.00%0.00%Better than Bitcoin? The Biotech Stock with 46,751% Potential (Ad)4x Better than Bitcoin Bitcoin would have to go from $68,000 to $314,000 to match the 463% gains we saw with Immunogen in December.Get the name of the stock here >>>MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationBCLIBrainstorm Cell Therapeutics0.5018 of 5 stars0.03.00.04.70.60.00.6ERYPERYTECH PharmaN/AN/AN/AN/AN/AN/AN/AN/AFENCFennec Pharmaceuticals2.5191 of 5 stars3.50.00.00.02.42.51.9IDRAIdera PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/AAnalyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBCLIBrainstorm Cell Therapeutics2.00HoldN/AN/AERYPERYTECH PharmaN/AN/AN/AN/AFENCFennec Pharmaceuticals3.00Buy$17.3389.23% UpsideIDRAIdera PharmaceuticalsN/AN/AN/AN/ACurrent Analyst RatingsLatest BCLI, FENC, ERYP, and IDRA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/4/2024FENCFennec PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$17.00 ➝ $18.003/18/2024FENCFennec PharmaceuticalsCraig HallumSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$17.00 ➝ $18.003/18/2024FENCFennec PharmaceuticalsWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform$16.00(Data available from 4/25/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBCLIBrainstorm Cell TherapeuticsN/AN/AN/AN/A($0.08) per shareN/AERYPERYTECH Pharma$32.66M3.24N/AN/A$0.80 per share3.88FENCFennec Pharmaceuticals$21.25M11.68N/AN/A($0.43) per share-21.30IDRAIdera PharmaceuticalsN/AN/AN/A0.29$0.56 per shareN/AProfitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBCLIBrainstorm Cell Therapeutics-$17.19M-$0.41N/AN/AN/AN/AN/A-376.40%5/20/2024 (Estimated)ERYPERYTECH Pharma-$240KN/A0.00∞N/AN/AN/AN/AN/AFENCFennec Pharmaceuticals-$16.05M-$0.61N/A13.09N/A-75.50%N/A-73.64%5/9/2024 (Estimated)IDRAIdera Pharmaceuticals$98.09M-$0.32N/AN/AN/AN/A-68.74%-34.26%N/ALatest BCLI, FENC, ERYP, and IDRA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails4/1/2024Q4 2023BCLIBrainstorm Cell Therapeutics-$0.15-$0.11+$0.04-$0.11N/AN/A3/21/2024Q4 2023FENCFennec Pharmaceuticals$0.02-$0.10-$0.12-$0.10$9.47 million$9.74 millionDividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBCLIBrainstorm Cell TherapeuticsN/AN/AN/AN/AN/AERYPERYTECH PharmaN/AN/AN/AN/AN/AFENCFennec PharmaceuticalsN/AN/AN/AN/AN/AIDRAIdera PharmaceuticalsN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBCLIBrainstorm Cell TherapeuticsN/A0.240.24ERYPERYTECH Pharma0.323.653.65FENCFennec PharmaceuticalsN/A3.563.27IDRAIdera PharmaceuticalsN/A1.561.56OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBCLIBrainstorm Cell Therapeutics14.33%ERYPERYTECH Pharma1.09%FENCFennec Pharmaceuticals55.51%IDRAIdera Pharmaceuticals12.18%Insider OwnershipCompanyInsider OwnershipBCLIBrainstorm Cell Therapeutics5.45%ERYPERYTECH Pharma1.94%FENCFennec Pharmaceuticals11.25%IDRAIdera Pharmaceuticals5.05%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableBCLIBrainstorm Cell Therapeutics2968.34 million64.62 millionOptionableERYPERYTECH Pharma4934.12 million33.46 millionNot OptionableFENCFennec PharmaceuticalsN/A27.10 million24.05 millionOptionableIDRAIdera Pharmaceuticals3262.36 million59.21 millionOptionableBCLI, FENC, ERYP, and IDRA HeadlinesSourceHeadlineEkso Bionics (NASDAQ: EKSO)fool.com - April 11 at 12:41 PMKiniksa Pharmaceuticalsforbes.com - November 15 at 3:23 PMIdra Pin Codeindiatvnews.com - August 24 at 7:09 PMNabriva Therapeutics AG (NBRVF)investing.com - August 9 at 2:08 AMTesla's Switch to Giga Press Die Castings for Model 3 Eliminates 370 Partsdesignnews.com - May 21 at 8:54 AMMarginalianpr.org - April 26 at 9:17 PMA mysterious rift propels the story in ‘Take What You Need’washingtonpost.com - March 17 at 5:57 PMIdera Pharmaceuticals, Inc.: Idera Pharmaceuticals Announces Name Change to Aceragen, Inc. and Provides Near-Term Strategic Outlookfinanznachrichten.de - January 18 at 7:34 AMIdera Pharmaceuticals Announces Name Change to Aceragen, Inc. and Provides Near-Term Strategic ...bakersfield.com - January 17 at 11:33 AMIdera Pharmaceuticals Announces Name Change to Aceragen, Inc. and Provides Near-Term Strategic Outlookfinance.yahoo.com - January 17 at 11:33 AMWhy Bed Bath & Beyond Shares Are Trading Higher By 17%? Here Are Other Stocks Moving In Tuesday's Mid-Day Sessionmsn.com - January 10 at 7:29 PMIdera (IDRA) Stock Soars on GlaxoSmithKline Partnershipthestreet.com - January 4 at 12:55 PMIdera Pharmaceuticals, Inc.: Idera Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Corporate Updatefinanznachrichten.de - November 18 at 3:52 PMIdera Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Corporate Updatefinance.yahoo.com - November 14 at 5:55 PMIdera Pharma Acquires Rare Disease Player, Names New CEOfinance.yahoo.com - September 29 at 3:46 PMIdera Pharma Shares Rise Nearly 18% After Aceragen Acquisitionmarketwatch.com - September 28 at 6:34 PMIdera Pharmaceuticals Acquires Aceragenfinance.yahoo.com - September 28 at 6:34 PMIdera Pharmaceuticals Stock (NASDAQ:IDRA), Dividendsbenzinga.com - September 27 at 10:32 PMIdera Pharmaceuticals Reports Second Quarter 2022 Financial Resultsfinance.yahoo.com - August 9 at 9:26 PMIdera Pharmaceuticals Inc. [IDRA] Is Currently 16.02 above its 200 Period Moving Avg: What Does This Mean?dbtnews.com - May 18 at 5:18 PMIdera halts melanoma trial for cancer candidate after early positive resultsseekingalpha.com - May 17 at 6:10 PMWhy Are Idera Pharmaceuticals Shares Soaring Todayfinance.yahoo.com - May 17 at 6:10 PMIdera Pharmaceuticals Shares Positive Results from Investigator-Sponsored Trial in Melanoma Patients at Amsterdam UMCfinance.yahoo.com - May 17 at 8:18 AMIdera Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Corporate Updatefinance.yahoo.com - May 5 at 6:17 PMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsBrainstorm Cell TherapeuticsNASDAQ:BCLIBrainstorm Cell Therapeutics Inc., a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company, through its NurOwn proprietary cell therapy platform, leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival, and enhance neurological function. It is developing NurOwn, which has completed Phase III clinical trial for the treatment of amyotrophic lateral sclerosis; Phase II clinical trial for the treatment of progressive multiple sclerosis; and for the treatment of alzheimer's disease, as well as for other neurodegenerative diseases. The company was formerly known as Golden Hand Resources Inc. and changed its name to Brainstorm Cell Therapeutics Inc. in November 2004. Brainstorm Cell Therapeutics Inc. was incorporated in 2000 and is headquartered in New York, New York.ERYTECH PharmaNASDAQ:ERYPERYTECH Pharma S.A., a biopharmaceutical company, focus on development of red blood cell-based therapeutics for cancer and orphan diseases in France and the United States. It develops eryaspase, which is in Phase 3 clinical development for the treatment of second-line pancreatic cancer, and in Phase 2 stage for the treatment of triple-negative breast cancer and second-line acute lymphoblastic leukemia patients. The company also engages in developing erymethionase, a preclinical product candidate that consists of methionine-?-lyase in red blood cells to target the amino acid metabolism of cancer cells and induce tumor starvation. ERYTECH Pharma S.A. was incorporated in 2004 and is headquartered in Lyon, France.Fennec PharmaceuticalsNASDAQ:FENCFennec Pharmaceuticals Inc., a biopharmaceutical company, develops product candidates for use in the treatment of cancer in the United States. Its lead product candidate is the Sodium Thiosulfate, which has completed the Phase III clinical trial for the prevention of cisplatin induced hearing loss or ototoxicity in children. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014. Fennec Pharmaceuticals Inc. was founded in 1996 and is based in Research Triangle Park, North Carolina.Idera PharmaceuticalsNASDAQ:IDRAAceragen, Inc. is a clinical stage biopharmaceutical company, which focuses on the clinical development, and commercialization of drug candidates for both oncology and rare disease indications. The company was founded by Paul C. Zamecnik, Sudhir A. Agrawal, and James B. Wyngaarden on May 25, 1989 and is headquartered in Exton, PA. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.